Talquetamab Combos Show Survival Benefit in r/r Myeloma

Published Date: 17 Jun 2026

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.

2.

Knowing about and avoiding bladder cancer.

3.

Renewing the call for a national Cancer Patient's Bill of Rights

4.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

5.

improvements in the treatment of prostate cancer resistant to chemotherapy.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot